Roth Capital Cuts Earnings Estimates for Zevra Therapeutics
Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Free Report) – Analysts at Roth Capital decreased their FY2029 EPS estimates for shares of Zevra Therapeutics in a report issued on Tuesday, March 11th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings of $2.05 per share for the year, down from their previous forecast […]
